Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016, Article ID 4508376, 10 pages
http://dx.doi.org/10.1155/2016/4508376
Review Article

Local Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A Review

1Unit of General Surgery B, The Pancreas Institute, G.B. Rossi Hospital, University of Verona Hospital Trust, Verona, Italy
2Pancreatic Surgical Unit, Casa di Cura Pederzoli, Peschiera del Garda, Verona, Italy

Received 15 July 2015; Revised 28 October 2015; Accepted 13 January 2016

Academic Editor: Bence Sipos

Copyright © 2016 Salvatore Paiella et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Cancer Society, Cancer Facts & Figures 2013, American Cancer Society, 2013.
  2. H. G. Smeenk, T. C. K. Tran, J. Erdmann, C. H. J. van Eijck, and J. Jeekel, “Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?” Langenbeck's Archives of Surgery, vol. 390, no. 2, pp. 94–103, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Kleeff, C. Reiser, U. Hinz et al., “Surgery for recurrent pancreatic ductal adenocarcinoma,” Annals of Surgery, vol. 245, no. 4, pp. 566–572, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. G. Morganti, M. Massaccesi, G. La Torre et al., “A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer,” Annals of Surgical Oncology, vol. 17, no. 1, pp. 194–205, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Oettle, S. Post, P. Neuhaus et al., “Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial,” The Journal of the American Medical Association, vol. 297, no. 3, pp. 267–277, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. J. P. Neoptolemos, D. D. Stocken, H. Friess et al., “A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer,” The New England Journal of Medicine, vol. 350, no. 12, pp. 1200–1210, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. W. F. Regine, K. A. Winter, R. A. Abrams et al., “Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial,” The Journal of the American Medical Association, vol. 299, no. 9, pp. 1019–1026, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. C. M. R. Lima, M. R. Green, R. Rotche et al., “Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate,” Journal of Clinical Oncology, vol. 22, no. 18, pp. 3776–3783, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Poplin, Y. Feng, J. Berlin et al., “Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group,” Journal of Clinical Oncology, vol. 27, no. 23, pp. 3778–3785, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Louvet, R. Labianca, P. Hammel et al., “Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial,” Journal of Clinical Oncology, vol. 23, no. 15, pp. 3509–3516, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. V. Heinemann, M. Haas, and S. Boeck, “Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer,” Annals of Oncology, vol. 24, no. 10, pp. 2484–2492, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Huguet, N. Girard, C. S. Guerche, C. Hennequin, F. Mornex, and D. Azria, “Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review,” Journal of Clinical Oncology, vol. 27, no. 13, pp. 2269–2277, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. S. J. E. Rombouts, J. A. Vogel, H. C. van Santvoort et al., “Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer,” British Journal of Surgery, vol. 102, no. 3, pp. 182–193, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. E. M. W. Sonnenberg and L. Solbiati, Tumor Ablation, Springer, New York, NY, USA, 2005.
  15. M. G. Keane, K. Bramis, S. P. Pereira, and G. K. Fusai, “Systematic review of novel ablative methods in locally advanced pancreatic cancer,” World Journal of Gastroenterology, vol. 20, no. 9, pp. 2267–2278, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Girelli, I. Frigerio, A. Giardino et al., “Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma,” Langenbeck's Archives of Surgery, vol. 398, no. 1, pp. 63–69, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Giardino, R. Girelli, I. Frigerio et al., “Triple approach strategy for patients with locally advanced pancreatic carcinoma,” HPB, vol. 15, no. 8, pp. 623–627, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. J. D. Spiliotis, A. C. Datsis, N. V. Michalopoulos et al., “Radiofrequency ablation combined with palliative surgery may prolong survival of patients with advanced cancer of the pancreas,” Langenbeck's Archives of Surgery, vol. 392, no. 1, pp. 55–60, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Wu, Z. Tang, H. Fang et al., “High operative risk of cool-tip radiofrequency ablation for unresectable pancreatic head cancer 1,” Journal of Surgical Oncology, vol. 94, no. 5, pp. 392–395, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Fegrachi, I. Q. Molenaar, J. H. Klaessens, M. G. Besselink, J. A. Offerhaus, and R. van Hillegersberg, “Radiofrequency ablation of the pancreas with and without intraluminal duodenal cooling in a porcine model,” The Journal of Surgical Research, vol. 184, no. 2, pp. 867–872, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Rossi, F. T. Viera, G. Ghittoni et al., “Radiofrequency ablation of pancreatic neuroendocrine tumors: a pilot study of feasibility, efficacy, and safety,” Pancreas, vol. 43, no. 6, pp. 938–945, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. T. J. Song, D. W. Seo, S. Lakhtakia et al., “Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer,” Gastrointestinal Endoscopy, vol. 83, no. 2, pp. 440–443, 2016. View at Publisher · View at Google Scholar
  23. R. C. G. Martin II, K. McFarland, S. Ellis, and V. Velanovich, “Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival,” Annals of Surgical Oncology, vol. 20, supplement 3, pp. S443–S449, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. R. C. Martin, D. Kwon, S. Chalikonda et al., “Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy,” Annals of Surgery, vol. 262, no. 3, pp. 486–494, 2015. View at Publisher · View at Google Scholar
  25. F. J. Trueba-Arguiñarena, D. S. de Prado-Otero, and R. Poves-Alvarez, “Pancreatic adenocarcinoma treated with irreversible electroporation case report: first experience and outcome,” Medicine, vol. 94, no. 26, p. e946, 2015. View at Publisher · View at Google Scholar
  26. G. Narayanan, P. J. Hosein, C. M. S. R. Lima et al., “Percutaneous irreversible electroporation (IRE) in the management of pancreatic cancer,” Journal of Clinical Oncology, vol. 32, supplement, abstract e15249, 2014. View at Google Scholar
  27. M. P. Belfiore, F. M. Ronza, F. Romano et al., “Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: our preliminary experience,” International Journal of Surgery, vol. 21, supplement 1, pp. S34–S39, 2015. View at Publisher · View at Google Scholar
  28. M. Pai, J. Yang, X. Zhang et al., “PWE-055 Endoscopic ultrasound guided radiofrequency ablation (EUS-RFA) for pancreatic ductal adenocarcinoma,” Gut, vol. 62, supplement 1, pp. A153–A153, 2013. View at Publisher · View at Google Scholar
  29. S. Paiella, G. Butturini, I. Frigerio et al., “Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study,” Digestive Surgery, vol. 32, no. 2, pp. 90–97, 2015. View at Publisher · View at Google Scholar
  30. B. Rubinsky, G. Onik, and P. Mikus, “Irreversible electroporation: a new ablation modality—clinical implications,” Technology in Cancer Research & Treatment, vol. 6, no. 1, pp. 37–48, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. R. V. Davalos, L. M. Mir, and B. Rubinsky, “Tissue ablation with irreversible electroporation,” Annals of Biomedical Engineering, vol. 33, no. 2, pp. 223–231, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Al-Sakere, F. André, C. Bernat et al., “Tumor ablation with irreversible electroporation,” PLoS ONE, vol. 2, no. 11, Article ID e1135, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. Z. Zhang, W. Li, D. Procissi, P. Tyler, R. A. Omary, and A. C. Larson, “Rapid dramatic alterations to the tumor microstructure in pancreatic cancer following irreversible electroporation ablation,” Nanomedicine, vol. 9, no. 8, pp. 1181–1192, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. E. W. Lee, D. Wong, S. V. Prikhodko et al., “Electron microscopic demonstration and evaluation of irreversible electroporation-induced nanopores on hepatocyte membranes,” Journal of Vascular and Interventional Radiology, vol. 23, no. 1, pp. 107–113, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. M. L. Yarmush, A. Golberg, G. Serša, T. Kotnik, and D. Miklavčič, “Electroporation-based technologies for medicine: principles, applications, and challenges,” Annual Review of Biomedical Engineering, vol. 16, pp. 295–320, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Golberg and M. L. Yarmush, “Nonthermal irreversible electroporation: fundamentals, applications, and challenges,” IEEE Transactions on Biomedical Engineering, vol. 60, no. 3, pp. 707–714, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Maor, A. Ivorra, J. Leor, and B. Rubinsky, “Irreversible electroporation attenuates neointimal formation after angioplasty,” IEEE Transactions on Biomedical Engineering, vol. 55, no. 9, pp. 2268–2274, 2008. View at Publisher · View at Google Scholar
  38. E. Maor, A. Ivorra, and B. Rubinsky, “Intravascular irreversible electroporation: theoretical and experimental feasibility study,” in Proceedings of the 30th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBS '08), pp. 2051–2054, Vancouver, Canada, August 2008. View at Publisher · View at Google Scholar
  39. H. Schoellnast, S. Monette, P. C. Ezell et al., “Acute and subacute effects of irreversible electroporation on nerves: experimental study in a pig model,” Radiology, vol. 260, no. 2, pp. 421–427, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Narayanan, S. Bhatia, A. Echenique, R. Suthar, K. Barbery, and J. Yrizarry, “Vessel patency post irreversible electroporation,” CardioVascular and Interventional Radiology, vol. 37, no. 6, pp. 1523–1529, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Faroja, M. Ahmed, L. Appelbaum et al., “Irreversible electroporation ablation: is all the damage nonthermal?” Radiology, vol. 266, no. 2, pp. 462–470, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. E. M. Dunki-Jacobs, P. Philips, and R. C. G. Martin II, “Evaluation of thermal injury to liver, pancreas and kidney during irreversible electroporation in an in vivo experimental model,” The British Journal of Surgery, vol. 101, no. 9, pp. 1113–1121, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Marčan, D. Pavliha, B. Kos, T. Forjanič, and D. Miklavčič, “Web-based tool for visualization of electric field distribution in deep-seated body structures and planning of electroporation-based treatments,” BioMedical Engineering OnLine, vol. 14, supplement 3, article S4, 2015. View at Publisher · View at Google Scholar
  44. A. Zupanic, B. Kos, and D. Miklavcic, “Treatment planning of electroporation-based medical interventions: electrochemotherapy, gene electrotransfer and irreversible electroporation,” Physics in Medicine and Biology, vol. 57, no. 17, pp. 5425–5440, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Miklavcic and R. V. Davalos, “Electrochemotherapy (ECT) and irreversible electroporation (IRE)—advanced techniques for treating deep-seated tumors based on electroporation,” BioMedical Engineering OnLine, vol. 14, supplement 3, article I1, 2015. View at Publisher · View at Google Scholar
  46. R. C. G. Martin, “Irreversible electroporation of locally advanced pancreatic head adenocarcinoma,” Journal of Gastrointestinal Surgery, vol. 17, no. 10, pp. 1850–1856, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. R. C. G. Martin, P. Philips, S. Ellis, D. Hayes, and S. Bagla, “Irreversible electroporation of unresectable soft tissue tumors with vascular invasion: effective palliation,” BMC Cancer, vol. 14, article 540, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Tosolini, C. W. Michalski, and J. Kleeff, “Response evaluation following neoadjuvant treatment of pancreatic cancer patients,” World Journal of Gastrointestinal Surgery, vol. 5, no. 2, pp. 12–15, 2013. View at Publisher · View at Google Scholar
  49. C. R. Ferrone, G. Marchegiani, T. S. Hong et al., “Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer,” Annals of Surgery, vol. 261, no. 1, pp. 12–17, 2015. View at Publisher · View at Google Scholar
  50. I. Frigerio, R. Girelli, A. Giardino, P. Regi, R. Salvia, and C. Bassi, “Short term chemotherapy followed by radiofrequency ablation in stage III pancreatic cancer: results from a single center,” Journal of Hepato-Biliary-Pancreatic Sciences, vol. 20, no. 6, pp. 574–577, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Girelli, I. Frigerio, R. Salvia, E. Barbi, P. Tinazzi Martini, and C. Bassi, “Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer,” British Journal of Surgery, vol. 97, no. 2, pp. 220–225, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Cantore, R. Girelli, A. Mambrini et al., “Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma,” The British Journal of Surgery, vol. 99, no. 8, pp. 1083–1088, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. A. K. Siriwardena, “Radiofrequency ablation for locally advanced cancer of the pancreas,” Journal of the Pancreas, vol. 7, no. 1, pp. 1–4, 2006. View at Google Scholar · View at Scopus
  54. A. W. Steel, A. J. Postgate, S. Khorsandi et al., “Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction,” Gastrointestinal Endoscopy, vol. 73, no. 1, pp. 149–153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. P. Hadjicostas, N. Malakounides, C. Varianos, E. Kitiris, F. Lerni, and P. Symeonides, “Radiofrequency ablation in pancreatic cancer,” HPB, vol. 8, no. 1, pp. 61–64, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Figueroa-Barojas, M. R. Bakhru, N. A. Habib et al., “Safety and efficacy of radiofrequency ablation in the management of unresectable bile duct and pancreatic cancer: a novel palliation technique,” Journal of Oncology, vol. 2013, Article ID 910897, 5 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Varshney, A. Sewkani, S. Sharma et al., “Radiofrequency ablation of unresectable pancreatic carcinoma: feasibility, efficacy and safety,” Journal of the Pancreas, vol. 7, no. 1, pp. 74–78, 2006. View at Google Scholar · View at Scopus
  58. R. Casadei, C. Ricci, R. Pezzilli et al., “A prospective study on radiofrequency ablation locally advanced pancreatic cancer,” Hepatobiliary & Pancreatic Diseases International, vol. 9, no. 3, pp. 306–311, 2010. View at Google Scholar · View at Scopus
  59. Y. Matsui, A. Nakagawa, Y. Kamiyama, K. Yamamoto, N. Kubo, and Y. Nakase, “Selective thermocoagulation of unresectable pancreatic cancers by using radiofrequency capacitive heating,” Pancreas, vol. 20, no. 1, pp. 14–20, 2000. View at Publisher · View at Google Scholar · View at Scopus
  60. R. S. Date and A. K. Siriwardena, “Radiofrequency ablation of the pancreas. II: intra-operative ablation of non-resectable pancreatic cancer. A description of technique and initial outcome,” Journal of the Pancreas, vol. 6, no. 6, pp. 588–592, 2005. View at Google Scholar · View at Scopus
  61. R. Waitz and S. B. Solomon, “Can local radiofrequency ablation of tumors generate systemic immunity against metastatic disease?” Radiology, vol. 251, no. 1, pp. 1–2, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Tiong and G. J. Maddern, “Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma,” The British Journal of Surgery, vol. 98, no. 9, pp. 1210–1224, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. M. D'Onofrio, G. Zamboni, N. Faccioli, P. Capelli, and R. Pozzi Mucelli, “Ultrasonography of the pancreas. 4. Contrast-enhanced imaging,” Abdominal Imaging, vol. 32, no. 2, pp. 171–181, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. M. W. Sweesy, J. L. Holland, and K. W. Smith, “Electromagnetic interference in cardiac rhythm management devices,” AACN Clinical Issues, vol. 15, no. 3, pp. 391–403, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. R. C. G. Martin II, K. McFarland, S. Ellis, and V. Velanovich, “Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma,” Journal of the American College of Surgeons, vol. 215, no. 3, pp. 361–369, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. S. Bagla and D. Papadouris, “Percutaneous irreversible electroporation of surgically unresectable pancreatic cancer: a case report,” Journal of Vascular and Interventional Radiology, vol. 23, no. 1, pp. 142–145, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. C. Mansson, M. Bergenfeldt, R. Brahmstaedt, B.-M. Karlson, P. Nygren, and A. Nilsson, “Safety and preliminary efficacy of ultrasound-guided percutaneous irreversible electroporation for treatment of localized pancreatic cancer,” Anticancer Research, vol. 34, no. 1, pp. 289–293, 2014. View at Google Scholar · View at Scopus
  68. M. J. Weiss and C. L. Wolfgang, “Irreversible electroporation: a novel pancreatic cancer therapy,” Current Problems in Cancer, vol. 37, no. 5, pp. 262–265, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. P. Philips, D. Hays, and R. C. G. Martin, “Irreversible electroporation ablation (IRE) of unresectable soft tissue tumors: learning curve evaluation in the first 150 patients treated,” PLoS ONE, vol. 8, no. 11, Article ID e76260, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. E. M. Dunki-Jacobs, P. Philips, and R. C. G. Martin II, “Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas,” Journal of the American College of Surgeons, vol. 218, no. 2, pp. 179–187, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Venkat, P. J. Hosein, and G. Narayanan, “Percutaneous approach to irreversible electroporation of the pancreas: Miami protocol,” Techniques in Vascular and Interventional Radiology, vol. 18, no. 3, pp. 153–158, 2015. View at Publisher · View at Google Scholar
  72. G. Narayanan, P. J. Hosein, G. Arora et al., “Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma,” Journal of Vascular and Interventional Radiology, vol. 23, no. 12, pp. 1613–1621, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. D. Kwon, K. McFarland, V. Velanovich, and R. C. G. Martin II, “Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation,” Surgery, vol. 156, no. 4, pp. 910–922, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. G. Narayanan, “Irreversible electroporation for treatment of liver cancer,” Gastroenterology & Hepatology, vol. 7, no. 5, pp. 313–316, 2011. View at Google Scholar · View at Scopus
  75. A. Deodhar, T. Dickfeld, G. W. Single et al., “Irreversible electroporation near the heart: ventricular arrhythmias can be prevented with ECG synchronization,” American Journal of Roentgenology, vol. 196, no. 3, pp. W330–W335, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. P. Philips, Y. Li, S. Li, C. R. St Hill, and R. C. Martin, “Efficacy of irreversible electroporation in human pancreatic adenocarcinoma: advanced murine model,” Molecular Therapy—Methods & Clinical Development, vol. 2, Article ID 15001, 2015. View at Publisher · View at Google Scholar
  77. H. J. Scheffer, K. Nielsen, M. C. de Jong et al., “Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy,” Journal of Vascular and Interventional Radiology, vol. 25, no. 7, pp. 997–1011, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. S. S. Raman, D. S. K. Lu, D. J. Vodopich, J. Sayre, and C. Lassman, “Creation of radiofrequency lesions in a porcine model: correlation with sonography, CT, and histopathology,” American Journal of Roentgenology, vol. 175, no. 5, pp. 1253–1258, 2000. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Kranjc, F. Bajd, I. Sersa, E. J. Woo, and D. Miklavcic, “Ex vivo and in silico feasibility study of monitoring electric field distribution in tissue during electroporation based treatments,” PLoS ONE, vol. 7, no. 9, Article ID e45737, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. F. Mahmood, R. H. Hansen, B. Agerholm-Larsen, K. S. Jensen, H. K. Iversen, and J. Gehl, “Diffusion-weighted MRI for verification of electroporation-based treatments,” Journal of Membrane Biology, vol. 240, no. 3, pp. 131–138, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. Guo, Y. Zhang, G. M. Nijm et al., “Irreversible electroporation in the liver: contrast-enhanced inversion-recovery MR imaging approaches to differentiate reversibly electroporated penumbra from irreversibly electroporated ablation zones,” Radiology, vol. 258, no. 2, pp. 461–468, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Kranjc, B. Markelc, F. Bajd et al., “In situ monitoring of electric field distribution in mouse tumor during electroporation,” Radiology, vol. 274, no. 1, pp. 115–123, 2015. View at Publisher · View at Google Scholar · View at Scopus
  83. J. F. Edd, L. Horowitz, R. V. Davalos, L. M. Mir, and B. Rubinsky, “In vivo results of a new focal tissue ablation technique: irreversible electroporation,” IEEE Transactions on Biomedical Engineering, vol. 53, no. 7, pp. 1409–1415, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. Y. J. Lee, D. S. K. Lu, F. Osuagwu, and C. Lassman, “Irreversible electroporation in porcine liver: acute computed tomography appearance of ablation zone with histopathologic correlation,” Journal of Computer Assisted Tomography, vol. 37, no. 2, pp. 154–158, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. L. Appelbaum, E. Ben-David, J. Sosna, Y. Nissenbaum, and S. N. Goldberg, “US findings after irreversible electroporation ablation: radiologic-pathologic correlation,” Radiology, vol. 262, no. 1, pp. 117–125, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. C. R. Schmidt, P. Shires, and M. Mootoo, “Real-time ultrasound imaging of irreversible electroporation in a porcine liver model adequately characterizes the zone of cellular necrosis,” HPB, vol. 14, no. 2, pp. 98–102, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. K. F. Chu and D. E. Dupuy, “Thermal ablation of tumours: biological mechanisms and advances in therapy,” Nature Reviews Cancer, vol. 14, no. 3, pp. 199–208, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Y. Ali, C. F. Grimm, M. Ritter et al., “Activation of dendritic cells by local ablation of hepatocellular carcinoma,” Journal of Hepatology, vol. 43, no. 5, pp. 817–822, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Evrard, C. Menetrier-Caux, C. Biota et al., “Cytokines pattern after surgical radiofrequency ablation of liver colorectal metastases,” Gastroentérologie Clinique et Biologique, vol. 31, no. 2, pp. 141–145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. A. M. Fietta, M. Morosini, I. Passadore et al., “Systemic inflammatory response and downmodulation of peripheral CD25+Foxp3+ T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer,” Human Immunology, vol. 70, no. 7, pp. 477–486, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. M. C. Jansen, S. van Wanrooy, R. van Hillegersberg et al., “Assessment of systemic inflammatory response (SIR) in patients undergoing radiofrequency ablation or partial liver resection for liver tumors,” European Journal of Surgical Oncology, vol. 34, no. 6, pp. 662–667, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Zerbini, M. Pilli, D. Laccabue et al., “Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response,” Gastroenterology, vol. 138, no. 5, pp. 1931.e2–1942.e2, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. J. Hänsler, T. T. Wissniowski, D. Schuppan et al., “Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases,” World Journal of Gastroenterology, vol. 12, no. 23, pp. 3716–3721, 2006. View at Google Scholar · View at Scopus
  94. C. Napoletano, F. Taurino, M. Biffoni et al., “RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients,” International Journal of Oncology, vol. 32, no. 2, pp. 481–490, 2008. View at Google Scholar · View at Scopus
  95. M. Widenmeyer, Y. Shebzukhov, S. P. Haen et al., “Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation,” International Journal of Cancer, vol. 128, no. 11, pp. 2653–2662, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. S. A. Dromi, M. P. Walsh, S. Herby et al., “Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity,” Radiology, vol. 251, no. 1, pp. 58–66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. P. Rovere-Querini and A. A. Manfredi, “Tumor destruction and in situ delivery of antigen presenting cells promote anti-neoplastic immune responses: implications for the immunotherapy of pancreatic cancer,” Journal of the Pancreas, vol. 5, no. 4, pp. 308–314, 2004. View at Google Scholar · View at Scopus
  98. S. R. Gameiro, J. P. Higgins, M. R. Dreher et al., “Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression,” PLoS ONE, vol. 8, no. 7, Article ID e70417, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. B. Al-Sakere, C. Bernat, F. André et al., “A study of the immunological response to tumor ablation with irreversible electroporation,” Technology in Cancer Research & Treatment, vol. 6, no. 4, pp. 301–305, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. X. Li, K. Xu, W. Li et al., “Immunologic response to tumor ablation with irreversible electroporation,” PLoS ONE, vol. 7, no. 11, Article ID e48749, 2012. View at Google Scholar · View at Scopus
  101. R. E. Neal II, J. H. Rossmeisl Jr., J. L. Robertson et al., “Improved local and systemic anti-tumor efficacy for irreversible electroporation in immunocompetent versus immunodeficient mice,” PLoS ONE, vol. 8, no. 5, Article ID e64559, 2013. View at Publisher · View at Google Scholar · View at Scopus
  102. P. McCulloch, D. G. Altman, W. B. Campbell et al., “No surgical innovation without evaluation: the IDEAL recommendations,” The Lancet, vol. 374, no. 9695, pp. 1105–1112, 2009. View at Publisher · View at Google Scholar · View at Scopus